Racial and ethnic disparities in opioid use for adolescents at US emergency departments.


Journal

BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804

Informations de publication

Date de publication:
31 05 2021
Historique:
received: 04 11 2019
accepted: 12 05 2021
entrez: 1 6 2021
pubmed: 2 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Racial/ethnic disparities in the use of opioids to treat pain disorders have been previously reported in the emergency department (ED). Further research is needed to better evaluate the impact race/ethnicity may have on the use of opioids in adolescents for the management of pain disorders in the ED. This was a cross-sectional study using data from the National Hospital Ambulatory Medical Care Survey from 2006 to 2016. Multivariate models were used to evaluate the role of race/ethnicity in the receipt of opioid agonists while in the ED. All ED visits with patients aged 11-21 years old were analyzed. Races/ethnicities were stratified as non-Hispanic Whites, non-Hispanic Blacks, and Hispanics. In addition to race, statistical analysis included the following covariates: pain score, pain diagnosis, age, region, sex, and payment method. There was a weighted total of 189,256,419 ED visits. Those visits involved 109,826,315 (58%) non-Hispanic Whites, 46,314,977 (24%) non-Hispanic Blacks, and 33,115,127 (18%) Hispanics, with 21.6% (95% CI, 21.1%-22.1), 15.2% (95% CI, 14.6-15.9%), and 17.4% (95% CI, 16.5-18.2%) of those visits reporting use of opioids, respectively. Regardless of age, sex, and region, non-Hispanic Whites received opioids at a higher rate than non-Hispanic Blacks and Hispanics. Based on diagnosis, non-Hispanic Whites received opioids at a higher rate in multiple pain diagnoses. Additionally, non-Hispanic Blacks and Hispanics were less likely to receive an opioid when reporting moderate pain (aOR = 0.738, 95% CI 0.601-0.906, aOR = 0.739, 95% CI 0.578-0.945, respectively) and severe pain (aOR = 0.580, 95% CI 0.500-0.672, aOR = 0.807, 95% CI 0.685-0.951, respectively) compared to non-Hispanic Whites. Differences in the receipt of opioid agonists in EDs among the races/ethnicities exist, with more non-Hispanic Whites receiving opioids than their minority counterparts. Non-Hispanic Black women may be an especially marginalized population. Further investigation into sex-based and regional differences are needed.

Sections du résumé

BACKGROUND
Racial/ethnic disparities in the use of opioids to treat pain disorders have been previously reported in the emergency department (ED). Further research is needed to better evaluate the impact race/ethnicity may have on the use of opioids in adolescents for the management of pain disorders in the ED.
METHODS
This was a cross-sectional study using data from the National Hospital Ambulatory Medical Care Survey from 2006 to 2016. Multivariate models were used to evaluate the role of race/ethnicity in the receipt of opioid agonists while in the ED. All ED visits with patients aged 11-21 years old were analyzed. Races/ethnicities were stratified as non-Hispanic Whites, non-Hispanic Blacks, and Hispanics. In addition to race, statistical analysis included the following covariates: pain score, pain diagnosis, age, region, sex, and payment method.
RESULTS
There was a weighted total of 189,256,419 ED visits. Those visits involved 109,826,315 (58%) non-Hispanic Whites, 46,314,977 (24%) non-Hispanic Blacks, and 33,115,127 (18%) Hispanics, with 21.6% (95% CI, 21.1%-22.1), 15.2% (95% CI, 14.6-15.9%), and 17.4% (95% CI, 16.5-18.2%) of those visits reporting use of opioids, respectively. Regardless of age, sex, and region, non-Hispanic Whites received opioids at a higher rate than non-Hispanic Blacks and Hispanics. Based on diagnosis, non-Hispanic Whites received opioids at a higher rate in multiple pain diagnoses. Additionally, non-Hispanic Blacks and Hispanics were less likely to receive an opioid when reporting moderate pain (aOR = 0.738, 95% CI 0.601-0.906, aOR = 0.739, 95% CI 0.578-0.945, respectively) and severe pain (aOR = 0.580, 95% CI 0.500-0.672, aOR = 0.807, 95% CI 0.685-0.951, respectively) compared to non-Hispanic Whites.
CONCLUSIONS
Differences in the receipt of opioid agonists in EDs among the races/ethnicities exist, with more non-Hispanic Whites receiving opioids than their minority counterparts. Non-Hispanic Black women may be an especially marginalized population. Further investigation into sex-based and regional differences are needed.

Identifiants

pubmed: 34059005
doi: 10.1186/s12887-021-02715-y
pii: 10.1186/s12887-021-02715-y
pmc: PMC8165785
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

252

Subventions

Organisme : NCI NIH HHS
ID : K08 CA179084
Pays : United States

Références

Pain. 2016 Oct;157(10):2173-2178
pubmed: 27227693
Ann Emerg Med. 2018 Jun;71(6):659-667.e3
pubmed: 29373155
JAMA Netw Open. 2018 Dec 7;1(8):e186558
pubmed: 30646334
J Health Care Poor Underserved. 2010 Feb;21(1):177-220
pubmed: 20173263
JAMA Pediatr. 2015 Nov;169(11):996-1002
pubmed: 26366984
BMJ. 2000 Apr 8;320(7240):980-1
pubmed: 10753150
Paediatr Anaesth. 2017 Jul;27(7):760-767
pubmed: 28504322
Pain Manag. 2017 Sep;7(5):427-453
pubmed: 28937312
J Pain. 2009 Dec;10(12):1187-204
pubmed: 19944378
JAMA. 2008 Jan 2;299(1):70-8
pubmed: 18167408
Pediatrics. 2005 Mar;115(3):e310-5
pubmed: 15741357
Congenit Heart Dis. 2010 May-Jun;5(3):285-91
pubmed: 20576048
Pediatrics. 2007 Jun;119(6):e1319-24
pubmed: 17545362
J Pediatr. 2019 Jul;210:20-25.e2
pubmed: 30955787
JAMA Intern Med. 2019 Feb 1;179(2):145-152
pubmed: 30508022
Am J Emerg Med. 2008 Mar;26(3):270-4
pubmed: 18358935
J Pediatr. 2014 Sep;165(3):618-21
pubmed: 24928697
Arch Pediatr Adolesc Med. 2012 Sep 1;166(9):797-802
pubmed: 22566521
J Pediatr Psychol. 2014 Nov-Dec;39(10):1149-60
pubmed: 25225182
Eur J Pain. 2006 Oct;10(7):587-95
pubmed: 16243549
Pain. 2018 Oct;159(10):2050-2057
pubmed: 29794611
Pain. 2005 Jan;113(1-2):20-6
pubmed: 15621360
Pediatrics. 2015 Nov;136(5):e1169-77
pubmed: 26504126
Pediatrics. 2017 Sep;140(3):
pubmed: 28827380
JAMA Netw Open. 2018 Dec 7;1(8):e186161
pubmed: 30646317
Ann Emerg Med. 2003 Jul;42(1):41-7
pubmed: 12827122

Auteurs

Michael T Phan (MT)

Chapman University, School of Pharmacy, Irvine, CA, 92618, USA.

Daniel M Tomaszewski (DM)

Department of Pharmaceutical & Health Economics, University of Southern California, School of Pharmacy, University Park Campus, 635 Downey Way, Bldg. #331, Los Angeles, CA, 90089, USA. dtomasze@usc.edu.

Cody Arbuckle (C)

Schmid College of Science and Technology, Chapman University, Orange, CA, 92866, USA.

Sun Yang (S)

Chapman University, School of Pharmacy, Irvine, CA, 92618, USA.

Candice Donaldson (C)

Irvine School of Medicine, University of California, Irvine, CA, 92617, USA.

Michelle Fortier (M)

Center on Stress & Health, University of California School of Medicine, Irvine, USA.
Department of Anesthesiology and Perioperative Care, University of California, Irvine, USA.
Department of Pediatric Psychology, Children's Hospital of Orange County, Orange, CA, USA.
Sue & Bill Gross School of Nursing, University of California, Irvine, CA, USA.
Department of Psychological Science, University of California, Irvine, CA, USA.

Brooke Jenkins (B)

Center on Stress & Health, University of California School of Medicine, Irvine, USA.
Department of Anesthesiology and Perioperative Care, University of California, Irvine, USA.
Department of Psychology, Chapman University, Orange, CA, 92866, USA.

Erik Linstead (E)

Schmid College of Science and Technology, Chapman University, Orange, CA, 92866, USA.

Zeev Kain (Z)

Center on Stress & Health, University of California School of Medicine, Irvine, USA.
Department of Anesthesiology and Perioperative Care, University of California, Irvine, USA.
Department of Pediatrics, CHOC Children's, Orange, CA, USA.
Yale Child Study Center, Yale University, New Haven, CT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH